Key Takeaways: BriaCell Therapeutics (BCTX) presented promising Phase 2 and 3 trial data at the 2025 San Antonio Breast Cancer Symposium.
News
- BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium - GuruFocus
- Novel endocrine therapy reduces the risk of breast cancer recurrence - Medical Xpress
The results were shared at the San Antonio Breast Cancer Symposium (SABCS) by global principal investigator, Dr. Aditya Bardia, professor of ...
- Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating ... - WVNews
... San Antonio Breast Cancer Symposium (SABCS) providing compelling mechanistic and early clinical evidence supporting the activity of paxalisib, the ...
- Pfizer's Tukysa delays HER2 breast cancer progression as 1st-line maintenance therapy
... San Antonio Breast Cancer Symposium. Patients who received the Pfizer ... Fierce Biotech · Fierce Healthcare · Fierce Pharma. Our Events. Life ...
- Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
Roche used the 2025 San Antonio Breast Cancer Symposium to share the ... Fierce Biotech · Fierce Healthcare. Our Events. Life Sciences Events.